The management of differentiated thyroid cancer using i for imaging to assess the need for i therapy

Nuclear Medicine Communications

Volumn 27, Issue 2, 2006, Pages 165-169

  Ali, Nidhal ^a   Sebastian, Cherry ^a   Foley, Rosemary R ^a   Murray, Iain ^a   Canizales, Ana L ^a   Jenkins, Paul J ^a   Drake, William M ^a   Nicholas Plowman, P ^a   Michael Besser, G ^a   Chew, Shern L ^a   Grossman, Ashley B ^a   Monson, John P ^a   Britton, Keith E ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Follicular; Papillary; Radioiodine; Thyroid cancer

Indexed keywords

IODINE 123; IODINE 131; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; THYROID CARCINOMA; THYROID SCINTISCANNING; ADOLESCENT; CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; PROGNOSIS; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE; WHOLE BODY IMAGING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 33645230419     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000194397.20067.b6     Document Type: Article

References (32)

1. Hundahl S, Fleming ID, Fremgen AM, Menck HR. A national cancer data-base on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer 1998; 83:2638-2648.
2. Schlumberger M, Tubiana M, De Vathaire F. Long term treatment results of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960-967.
3. Mazzaferri EL, Kloos RT. Clinical Review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447-1463.
4. Rawson RW, Rall JE, Peacock W. Limitation in the treatment of cancer of the thyroid with radioactive iodine. J Clin Endocrinol Metab 1951; 11:1128-1142.
5. 131I survey scanning in the management of differentiated thyroid carcinomas (Abstract). Eur J Nucl Med 1990; 16:407.
6. Jeevanram RK, Shah DH, Sharma SM, Kumar BS, Sharma SM, Gantra RD. Influence of initial large dose on subsequent uptake of therapeutic radioiodone in thyroid cancer patients. Nucl Med Biol 1986; 13:277-279.
7. Park H-M, Perkins OW, Edmonson JW. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994; 4:49-54.
8. Park H-M, Park Y-H, Zhou X-H. Detection of thyroid remnant/metastases without stunning: an ongoing dilemma. Thyroid 1997; 7:277-280.
9. 131I. Nucl Med Commun 1996; 17:839-842.
10. Lege FA, Izembart M, Dagousset F, Barrtault L, Baillet G, Chevalier A, Clerc J. Decreased uptake of therapeutic doses of iodine-131 after 185 MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25:242-246.
11. Britton KE, Granowska M. Radioimmunoscintigraphy in tumour identification. Cancer Surveys 1987; 6:247-267.
12. Britton KE. Aphorisms of nuclear medicine (Editorial). W J Nucl Med 2004; 3:186-188.
13. Morris LF, Waxman AD, Braunstein GD. Thyroid stunning. Thyroid 2003; 13:333-340.
14. 131I scans. Nucl Med Commun 2004; 25:129-134.
15. 131I tracer is negative but raised thyroglobulin,Tg. Eur J Nucl Med 1999; 26:1013.
16. 131I-scanning. Avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol 2001; 55:515-521.
17. Park HM. Invited commentary: I-123 almost a designer radioiodine for thyroid scanning. J Nucl Med 2002; 43:77-78.
18. Shankar LK, Yamamoto AJ, Alavi IA, Mandel SJ. Comparison of 1-123 scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med 2002; 43:72-76.
19. Britton KE, Foley RR, Chew SL. Should hTG levels in the absence of iodine uptake be treated? Eur J Nucl Med Mol Imaging 2003; 30:794-795.
20. Gulzar Z, Jana S, Young I, Bukberg P, Yen V, Naddaf S, Abdel-Dayem HM. Neck and whole body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer. Endocr Pract 2001; 7:244-249.
21. 131I therapy whole body scanning. J Clin Endocrinol Metab 2001; 86:5294-5300.
22. Lida Y, Hidaka A, Hatabu H, Kasagi K, Konishi J. Follow-up study of post-operative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement. J Nucl Med 1991; 32:2098-2100.
23. Yen T-C, Lin H-D, Lee C-H, Change SL, Yeh SH. The role of technetium-99m sestamibi whole body-scan in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectomy: a comparison with iodine-131 and thallium-201 whole body scans. J Nucl Med 1994; 21:980-983.
24. Rubello D, Mazzarotto R, Casara D. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med 2000; 27:431-440.
25. Gallowitsch H, Mikosch P, Kresnik E, Unterweger O, Gomez I, Linda P. Thyroglobulin and low dose iodine-131 and technetium-99m tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1998; 39:870-875.
26. McDougall IR, Davidson J, Segall GM. Positron emission tomography and the thyroid with an emphasis on thyroid cancer. Nucl Med Commun 2001; 22:485-492.
27. Schlumberger MJ. Papillary and follicular thyroid carcinoma. New Engl J Med 1998; 338:297-306.
28. Yaakob W, Gordon L, Spicer KM, Nike SJ. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases. J Nucl Med Technol 1999; 72:279-281.
29. Mandel SJ, Shanker LK, Bernand F, Alvai A. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnant patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26:6-9.
30. 123I diagnostic thyroid tumour whole-body scanning with imaging at 6, 24 and 48 hour. Clin Nucl Med 2002; 27:1-8.
31. 123I whole body scan and thyroglobulin in the detection of recurrent differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2002; 29:768-774.
32. Mazzaferri E, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role serum thyroglobulin as a monitoring method for low risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433-1441.